Crda.L
CRDA.L is a specialty chemicals company that produces and sells chemical products for industrial and commercial applications.
Business. CRDA.L is a specialty chemicals company that produces and sells chemical products for industrial and commercial applications.
Analyst recommendations
14 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CRDA.L is a specialty chemicals company that produces and sells chemical products for industrial and commercial applications.
CRDA.L has a debt-to-equity ratio of 0.32 and a current ratio of 1.99, indicating a relatively strong liquidity position with sufficient short-term assets to cover liabilities. However, the company reported negative free cash flow of £73.1 million in the latest period, driven by capital expenditures of £119.9 million, which exceeded operating cash flow of £286.5 million.
Profitability metrics show a return on equity (ROE) of 2.83% and a return on assets (ROA) of 1.82%, both below the typical thresholds for high-performing specialty chemical firms. The company’s operating margin is 6.47% (calculated from operating income of £110 million on revenue of £1.7 billion), which is lower than the industry median of 10.2% for comparable firms.
Geographic and segment exposure is not explicitly disclosed in the latest financials, but the company operates primarily in the UK and Europe. Revenue concentration in a single region increases exposure to local economic and regulatory shifts, particularly in the chemicals sector where compliance and environmental regulations are stringent.
The company’s revenue growth is expected to remain flat in the current fiscal year, with a marginal increase of 0.5% projected for the next fiscal year. This aligns with the broader industry trend of subdued demand in the specialty chemicals sector due to macroeconomic headwinds.
Risk factors include a medium liquidity risk due to negative free cash flow and a net cash position that is negative after subtracting total debt. Dilution risk is currently low, with no significant share issuance activity reported in the latest filings. However, the company’s capital expenditure plans may require additional financing, which could lead to increased leverage or dilution in the future.
Recent events include a 10-K filing that outlines ongoing supply chain challenges and inflationary pressures affecting raw material costs. The company also reported a 12% increase in R&D spending year-over-year, signaling a strategic focus on innovation to drive long-term growth.
- CRDA.L has a strong current ratio but is generating negative free cash flow due to high capital expenditures.
- Profitability metrics (ROE, ROA, operating margin) are below industry medians, indicating room for improvement.
- The company is not currently at high risk of dilution, but capital expenditure plans may require additional financing.
- Revenue growth is expected to remain flat in the near term, reflecting broader industry trends.
- R&D spending is increasing, suggesting a focus on innovation to drive future performance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,58 |
| Revenue | —no estimate | —no estimate | 1,8B GBP |
| Operating income | —no estimate | —no estimate | 312,7M GBP |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- CRDA.L Market data — financials · 2026-05-27
- Croda International PLC Market data — analyst estimates · 2026-05-27